Plain-English translation of NCT07124936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new drug called combined with chemotherapy treatments that are already used to treat a type of blood cancer called diffuse large B-cell lymphoma. Researchers want to see if adding this medication to standard treatments makes them work better and is safe for patients. The trial has two groups: one for people newly diagnosed with this cancer, and another for people whose cancer has come back after previous treatment.
Current treatments help many patients with this type of lymphoma, but some people either don't respond well or their cancer returns. This medication is being studied to see if it can improve how well standard treatments work and help more patients achieve long-term remission.
You likely qualify if…
You likely don't qualify if…
You would visit a cancer center every 3 weeks to receive intravenous infusions of the medication combined with standard chemotherapy drugs. Depending on which group you're in, you would receive 6 to 8 cycles of treatment, with each cycle lasting 3 weeks. Throughout the trial, you would have blood tests and imaging scans to monitor how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China